HomeCompareSTGC vs ABBV

STGC vs ABBV: Dividend Comparison 2026

STGC yields 1290.32% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STGC wins by $179862397.67M in total portfolio value
10 years
STGC
STGC
● Live price
1290.32%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$179862397.77M
Annual income
$156,069,016,072,097.00
Full STGC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — STGC vs ABBV

📍 STGC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTGCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STGC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STGC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STGC
Annual income on $10K today (after 15% tax)
$109,677.42/yr
After 10yr DRIP, annual income (after tax)
$132,658,663,661,282.45/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, STGC beats the other by $132,658,663,640,226.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STGC + ABBV for your $10,000?

STGC: 50%ABBV: 50%
100% ABBV50/50100% STGC
Portfolio after 10yr
$89931198.94M
Annual income
$78,034,508,048,434.38/yr
Blended yield
86.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

STGC
No analyst data
Altman Z
5.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STGC buys
0
ABBV buys
0
No recent congressional trades found for STGC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTGCABBV
Forward yield1290.32%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$179862397.77M$102.3K
Annual income after 10y$156,069,016,072,097.00$24,771.77
Total dividends collected$178102191.57M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: STGC vs ABBV ($10,000, DRIP)

YearSTGC PortfolioSTGC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$139,732$129,032.26$11,550$430.00+$128.2KSTGC
2$1,834,557$1,685,043.81$13,472$627.96+$1.82MSTGC
3$22,638,762$20,675,786.05$15,906$926.08+$22.62MSTGC
4$262,674,749$238,451,273.26$19,071$1,382.55+$262.66MSTGC
5$2,866,782,089$2,585,720,107.80$23,302$2,095.81+$2866.76MSTGC
6$29,441,340,826$26,373,883,990.04$29,150$3,237.93+$29441.31MSTGC
7$284,637,828,462$253,135,593,778.43$37,536$5,121.41+$284637.79MSTGC
8$2,591,764,208,133$2,287,201,731,679.32$50,079$8,338.38+$2591764.16MSTGC
9$22,236,805,328,760$19,463,617,626,057.21$69,753$14,065.80+$22236805.26MSTGC
10$179,862,397,773,870$156,069,016,072,097.00$102,337$24,771.77+$179862397.67MSTGC

STGC vs ABBV: Complete Analysis 2026

STGCStock

StartEngine Crowdfunding, Inc. is a startup accelerator specializing in technology sector. It was founded in 2014 and is based in Los Angeles, California.

Full STGC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this STGC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STGC vs SCHDSTGC vs JEPISTGC vs OSTGC vs KOSTGC vs MAINSTGC vs JNJSTGC vs MRKSTGC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.